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Summary The optimal drug-light interval for effective photodynamic therapy (PDT) of early squamous cell carcinomas was evaluated with
tetra(m-hydroxyphenyl)chlorin (mTHPC) by means of two complementary modalities: irradiation tests and ex vivo fluorescence microscopy. A
Syrian hamster cheek pouch tumour model was used in these experiments. Photodynamic therapy on both tumour-bearing and contralateral
healthy cheek pouch mucosae was performed at 650 nm and 514 nm. Light doses of 12 J cm-2 were delivered at a light dose rate of
150 mW cm-2 and light doses of 80 J cm-2 were delivered at a light dose rate of 100 mW cm-2 respectively, atthese twowavelengths, between
6 h and 12 days after the injection of 0.5 mg kg-' body weight mTHPC. Two histologically different types of tissue damage were observed:
first, a non-selective and non-specific ischaemic vascular necrosis for the cases in which PDT took place during the first 48 h after the
injection of the dye and, second, tissue-specific PDT damage, as a coagulation necrosis, when PDT took place more than 72 h after injection
of the dye. The time-dependent biodistribution of mTHPC investigated by fluorescence microscopy shows a weak and non-significant
difference in relative fluorescence intensities between early SCC and healthy mucosae. Up to 2 days after the injection, the drug is mainly
localized in the endothelial cells of the blood vessels. After this period, the dye accumulates in the squamous epithelia with a concentration
peaking at 4 days. At all time points, a weak fluorescence intensity is observed in the underlying lamina propria and striated muscle. The
information obtained from these studies could well be relevant to clinical trials as it suggests that time delays between 4 and 8 days after i.v.
injection should be optimal for PDT of early malignancies in hollow organs.
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In photodynamic therapy (PDT), activation of the photosensitizer
(PS) by light of the appropriate wavelength results in photodamage
oftargeted tissues (Henderson and Dougherty, 1992a; Kessel, 1990).
This therapeutic modality has been shown to be apromising alterna-
tive fortreating early squamous cell cancers (SCC) in hollow organs
(Edell and Cortese, 1992; Furuse et al., 1993; Grant et al., 1993;
Hayata et al., 1993). In headandneckcancers, the advantage ofPDT
compared with other conventional modalities such as surgery, radia-
tion therapy or chemotherapy, lies in the limited destruction of
normal tissue surrounding the tumour, which reduces the risk of
significant functional disorders such as dysphagia (Biel, 1995).
The first generation PSs (Photofrin I and II) were tested in clin-
ical studies in the ENTClinic inLausanne, starting in 1984 with the
treatment of early SCC in the upper aerodigestive tract, tracheo-
bronchial tree and oesophagus (Monnier et al., 1990). From 1992,
the tetra(m-hydroxyphenyl)chlorin, now known under the trade
name Foscan has been introduced in our preclinical (Andrejevic
et al., 1996a; Andrejevic-Blant et al., 1996, 1997) and clinical
trials (Braichotte et al., 1995; Grosjean et al., 1996). mTHPC has a
well-defined chemical structure and is available with greater than
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98% purity. Itexhibits alarge excitation coefficient at650 nm and a
somewhat smaller one at 514 nm and has a high quantum yield
for singlet oxygen production (Berenbaum et al., 1986, 1993).
Moreover, it is an extremely phototoxic compound in vivo and has
a high fluorescence quantum yield that can be used for light-
induced fluorescence spectroscopy and photodiagnostic imaging
(Braichotte et al., 1995; Grosjean et al., 1996).
Among the large number of parameters (i.e. type of PS, drug
dose, light dose, light dose rate) influencing effective PDT, the
drug-light interval is obviously crucial for optimizing the thera-
peutic effect. As it is difficult to optimize all ofthese variables in a
clinical context, the use of an animal model may provide preclin-
ical data relevant for clinical PDT trials. We have chosen the early
SCC, chemically induced by 7,12-dimethylbenz(a)anthracene
(DMBA) in the cheek pouch of the Syrian hamster (Salley, 1954;
Andrejevic et al., 1996b). However, the biodistribution ofmTHPC
in this model may be especially relevant, as hamsters, like humans,
have similar levels of circulating low (LDL) and high (HDL)-
density lipoprotein (Chapman, 1986).
The chemical properties ofthe dye, its mode ofdelivery and the
time interval between drug administration and light application
can affect the biodistribution and consequently the mechanism of
PDT-induced tissue destruction (Peng et al., 1996). Studies on
different tumour models suggest that, apart from the drug-light
interval, the type and staging of the tumour as well as its vascular
and lymphatic patterns may greatly influence the time-dependent
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uptake, retention and elimination ofthe same dye (Whelpton et al.,
1995). The photodynamic responses have in some cases been
correlated with the detailed biodistribution of the first- and
second-generation PSs actually used in preclinical and clinical
trials, such as porphyrins, phthalocyanines, chlorins or 5-amino-
laevulinic acid-induced protoporphyrin IX (Kessel and Woodburn,
1993). Different methods, such as chemical extraction assay (Peng
et al., 1995), spectroscopy (Morlet et al., 1995), fluorescence
microscopy (Barr et al., 1988) and radiolabelling (Hua et al.,
1995), used in these studies have shown that there is no true selec-
tivity between the tumour and other organs or tissues. Some time-
dependent 'selectivity' in dye localization has been observed for
implanted, well-vascularized bulky tumours, compared with
surrounding structures such as striated muscle and skin (Bedwell
et al., 1992; linuma et al., 1995; Peng et al., 1995). These data
point to the fact that the biodistribution ofthe dye should be eval-
uated for each neoplasm in its clinical context to set up an optimal
drug-light interval for PDT. In recent preclinical studies, the effect
of the drug-light interval on mTHPC-PDT has been reported for
bulky invasive tumours such as skin papillomas and malignant
mesothelioma (Ris et al., 1993b; Lofgren et al., 1994).
The aim of the present study was to evaluate the optimal
drug-light interval for effective PDT of early SCC. For this
purpose, photodynamic efficiency at various drug-light intervals
was compared with the time-dependent biodistribution ofmTHPC
for both tumour-bearing and healthy cheek pouch mucosae of the
Syrian hamster. Fluorescence microscopy studies were used to
quantify exogene time-dependent dye fluorescence in different
tissues and tissue compartments. This method may help us to
improve our understanding ofthe mechanism ofPDT injury.
MATERIAL AND METHODS
Animal model
Chemically induced early SCCs (carcinoma in situ and micro-
invasive carcinoma) of the Syrian hamster cheek pouch (BRL,
Fuellinsdorf, Switzerland) were induced by topical application
of 0.5% oily DMBA (Sigma Chemicals, St Louis, MO, USA)
solution in the left cheek pouch mucosa three times weekly for
10 weeks (Andrejevic et al., 1996b). The contralateral cheek
pouch, which was not painted with DMBA, served as control.
Animals were housed at room temperature with a 12-hour
light-dark cycle. Free access to food and drinking water was
allowed throughout the experiments. Photodynamic therapy was
performed under intraperitoneal anaesthesia (Ketalar 150 mg kg-'
and Xylesine 15 mg kg-') following the protocol approved by the
Experimental Animal Ethics Committee.
Light source and light delivery
An argon-ion pumped dye laser (Spectra-Physics model 2045
argon-ion laser and Spectra-Physics model 375 B dye laser),
operating with DCM dye (dye LC 6500 from Lambda Physics), was
used as the light source at650 nm, whereas forirradiation at514 nm
the argon-ion laser operated in the single line mode was used. The
light is applied using a cylindrical distributor of 1 cm diameter
equipped with a lateral circular window (Andrejevic-Blant et al.,
1996, 1997). The appropriate size and careful positioning of the
light diffuser in the hamster cheek pouch in direct contact with the
buccal mucosa allowed precise control ofthe light dosimetry.
Table 1 Tissue damage scale
Grades of tissue damage Histology
0 No tissue destruction
1 Destruction of the epithelium
2 Destruction of the epithelium and the lamina
propria
3 Destruction of the epithelium, the lamina
propria and the striated muscle
4 Destruction of all layers resulting in
transmural necrosis
Grades 0 and 1 are estimated as insufficient, 2 and 3 as optimal and 4 as
overdose responses.
Photodynamic therapy
The mTHPC was obtained as a lyophilized powder (Scotia
Pharmaceuticals, Guildford, UK) and freshly prepared by
dissolving it in a mixture of 30% polyethylene glycol 400, 20%
(v/v) ethanol and 50% (v/v) water. After intracardiac injection of
0.5 mg kg-', irradiation tests on tumour-bearing and contralateral
healthy cheek pouch were performed at 650 and 514 nm at various
times between 6 and 12 days. Parameters such as drug dose, light
dose and light dose rate (Andrejevic-Blant et al., 1996, 1997) were
adapted to those already applied in clinical trials (Grosjean et al.,
1996). At 650 nm, the fluence of 12 J cm-2 was delivered at a
fluence rate of 150 mW cm-2, whereas at 514 nm the fluence of
80 J cm-2 was delivered at a fluence rate of 100 mW cm-2. To
support the discussion section, PDT response at 650 nm using
various light dose regimens was compared at sensitization times of
1, 4 and 8 days. The fluences ranging from 0.75 to 20 J cm-2 were
delivered at a fluence rate of 150 mW cm-2.
Analysis of PDT-induced tissue damage
The animals were killed by an overdose of the anaesthesia 96 h
after PDT, which corresponds to the time of maximal mucosal
damage. For each animal, the necrotic area was examined in
haematoxylin and eosin (HE)-stained serial sections. In order to
evaluate the histological depth of PDT damage on different
mucosal layers, such as epithelium, lamina propria or striated
muscle, a four-grade tissue damage scale was used (Andrejevic-
Blant et al., 1996, 1997). Grades ofthe necrosis and evaluation of
the tissue damage are summarized in Table 1.
Fluorescence microscopy
The time-dependent biodistribution ofmTHPC in eitherearly SCC
or healthy cheek pouch mucosae was assessed separately using
ex vivo fluorescence microscopy (Andrejevic et al., 1996a). This
quantitative technique permits localization ofvarious fluorescence
levels ofthe PS in different tissues and tissue compartments (such
as epithelium, lamina propria, striated muscle or blood vessels),
reflecting the metabolism and pharmacokinetics of the dye. After
intracardiac injection of 0.5 mg kg-' body weight of mTHPC,
groups of three animals were sacrificed at different time intervals
up to 12 days (6 h, 12 h, 1, 2, 3, 4, 6, 8 and 12 days). The speci-
mens were fast frozen in liquid nitrogen by contact with isopentan
slush and stored at -70°C before use. Tissue sections were
prepared and imaged in the dark to avoid photobleaching of
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Figure 1 (A) PDT-induced tissue damage in early SCCs (- 4 ) and healthy (---Z---) mucosae at 650 nm, after injection of 0.5 mg kg-' mTHPC, as a function
of time. The fluence of 12 J cm-2 is delivered at fluence rate of 150 mW cm-2. Optimal PDT responses on SCC are achieved between 3 and 8 days, whereas
damage to the healthy mucosa diminishes significantly between these two time points. (B) PDT-induced tissue damage in early SCCs ( - ) and healthy
(---O---)mucosae at 514 nm, after injection of 0.5 mg kg-' mTHPC, as a function of time. The fluence of 80 J cm-2 is delivered at fluence rate of 100 mW cm-2.
Optimal PDT responses on SCC are achieved between 4 and 8 days and the curve pattern over the time is similar to those seen in A. PDTdamage was
assessed 96 h after light exposure. All data points represent mean tissue damage for five animals as determined by the rating scale described in the text. Error
bars are +1 standard deviation. The significance of the tissue response observed between neoplastic and healthy mucosae at various drug-light intervals is
determined using a non-parametric Mann-Whitney U-test (a < 0.05). The S-shaped Gompertz formula curve used is described in Material and methods
mTHPC. The frozen tissue blocks were mounted in OCT medium
(Tissue Tek II embedding compound, BDH) and a series of
sections cut with a cryostat (Frigocut Model 2700, Reichert).
Three consecutive non-stained 4-jim-thick tissue sections mounted
on clean glass slides were prepared for each sample. From each
section, three images were recorded over three different parts of
the slice to avoid photobleaching. We used an Olympus BH-2
epifluorescence microscope with a filtered 100-W mercury lamp
as the excitation light source. Images were taken with a cooled
slow-scan 16-bit CCD camera (EEV P86231, Wright Institute,
Endfield, UK). For excitation, an interference bandpass filter
420DF30 (Omega Optical, Brattleboro, VT, USA) and a dichroic
mirror at 470 nm were used. A long-pass filter RG 630 (Schott,
Mainz, Germany) was used to record the fluorescence ofmTHPC,
and an interference bandpass filter 560DF40 (Omega) was used to
record the tissue autofluorescence. The CCD camera was used
with an excitation shutter (Uniblitz Model D122, Vincent,
Rochester, NY, USA) to avoid photobleaching. The system was
controlled by an IBM-PC computer using ATI software (Wright
Institute). Sixteen-bit image processing was done using the same
software. The localization and intensity of the dye fluorescence
were ascertained by subtracting the autofluorescence from the
fluorescence image. This autofluorescence background subtraction
procedure was standardized on blank samples, which were tissue
slices from uninjected animals. Flat field correction was done
using a fluorescent reference sample (Uranyl Glass, donation from
LPBC, Paris VI, France, absorption 300-510nm, fluorescence
emission 500-600 nm with peaks at 514 and 533 nm). The relative
fluorescence intensity ofdifferent mucosal layers was analysed on
a Macintosh computer using the public domain NIH Image 1.59
program (US National Institutes of Health, available on the
Internet at http://rsb.info.nih.gov/nih-image/). After recording the
fluorescence image, the same slices were carefully removed and
stained with HE. An HE image was recorded at the exact identical
position and was compared with the fluorescence image in order to
determine the histological localization of mTHPC.
Statistical analysis
The significance of the differences in PDT responses achieved on
neoplastic and healthy mucosae was determined using a non-para-
metric Mann-Whitney U-test (a < 0.05). Despite the fact that our
tissue damage scale is not linear, the data were fitted with an S-
shaped Gompertz formula curve (y = a exp (-b exp (kt)) for visual
support.
The significance of the fluorescence intensities measured in
blood vessels, neoplastic and healthy mucosae at different time
intervals was determined according to the same test and data
points were fitted with an uptake elimination mathematical model
(y = a exp (-bt) (1-exp(-ct))) for visual support.
RESULTS
Photodynamic therapy
Macroscopically, the first changes on the tumour-bearing or
healthy mucosae were observed 24 h after PDT, as a diffuse
oedema ofthe whole cheek pouch. The first visible tissue reaction
matching the irradiation window appeared 48 h later. The maximal
tissue damage on either mucosae was observed 96 h after PDT.
Control animals treated with the same irradiation regimen but
without mTHPC injection showed no tissue damage at all. In all
cases, and at both wavelengths applied, the results were fairly
reproducible and very similar in different groups of animals. At
short drug-light intervals (i.e. up to 48 h), no significant differ-
ences in PDT damage between tumour and healthy mucosae were
seen. At drug-light intervals between 3 and 12 days, significantly
greater PDT damage (a < 0.05) was observed for early SCCs
compared with the healthy mucosae.
Figure IA illustrates the grades of PDT-induced tissue damage
at 650 nm between 6 h and 12 days after mTHPC injection. A
transmural necrosis was observed for both SCC and healthy
mucosae for PDT performed up to 2 days after dye administration.
Histology identified an ischaemic necrosis with structural
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evidence ofcell death mainly due to vascular damage and hypoxia.
Considerable oedema with vascular dilation and migration of
white cells within the dilated vessels, as well as some focal haem-
orrhage were also seen (Figure 2A and B). This tissue reaction was
judged as a non-suitable 'overdose' response. If PDT takes place
between 3 and 8 days after the injection of mTHPC, greater
destruction is observed for the SCC than for the healthy mucosa
(c < 0.05). At these longer time delays, histology presented a
predominant coagulation necrosis probably due to direct cell
death, with a partially resorbed oedema, minimal vascular dilata-
tion and less prominent vascular damage. Acute inflammatory
changes were also observed. The main characteristics of coagula-
tion necrosis are more pronounced eosin staining and preservation
of general tissue architecture, despite the death of the cells.
Optimal PDT responses on SCC were achieved between 3 and
8 days after injection, with only a slight decrease of tumour
damage between 4 days (Figure 2C and D) and 8 days (Figure 2E
and F). Damage on the healthy mucosa diminished significantly
(x < 0.05) between these two time points. The SCC damage
observed after PDT between 9 and 12 days was estimated to be an
insufficient PDT response. Histologically, essentially the same
grade of necrosis, although less pronounced oedema, was
observed for the PDT response at 514 nm (Figure IB).
Fluorescence microscopy
Separate experiments were carried out using fluorescence
microscopy. A series offluorescence micrographs were taken from
biopsies of early SCC and contralateral healthy cheek pouch
mucosa in animals injected with mTHPC at times varying from 6 h
to 12 days. The ratio between dye fluorescence and autofluores-
cence decreased over time. Dye fluorescence could be imaged for
biopsies taken up to 12 days after injection. However, the relative
intensities were widely distributed in different tissues and tissue
compartments at various time points.
Each point in Figure 3A-C represents the single measurement
of the relative fluorescence intensity from blood vessel walls and
different compartments of the healthy and SCC mucosae. Inter-
animal variations seemed to be of the same order of magnitude in
the different tissue compartments. Up to 48 h, the highest dye
fluorescence was found in the vasculature, with a maximum
around 12 h. Between 3 and 8 days after injection, the fluores-
cence was mainly observed in the epithelia, and thereafter the
fluorescence intensity considerably diminished in all tissues and
tissue compartments. A low, time-dependent, mTHPC fluores-
cence was detected in the underlying lamina propria and striated
muscle. Furthermore, a weak and non-significant difference in
relative fluorescence intensity was noted between early SCCs and
healthy epithelia (a > 0.05).
The histology of PDT-induced damage at different drug-light
intervals was correlated with the time-dependent dye localization
in various tissues and tissue compartments. Figure 4 illustrates the
series of fluorescence photomicrographs that correspond to the
three drug-light intervals presented in Figure 2 (12 h, 4 and 8 days).
Figure 4A and B are fluorescence photomicrographs and the
corresponding HE staining of the cheek pouch mucosa 12 h after
injection of mTHPC. The fluorescence appears primarily in the
endothelial cells ofthe blood vessels situated in the lamina propria
and in a few inflammatory cells or monocytes/macrophages
surrounding the vascular bed. A weak fluorescence intensity is
observed in all mucosal layers (epithelium, lamina propria, striated
muscle). The fluorescence photomicrographs and corresponding
HE stains recorded at 4 days (Figure 4C and D) and 8 days (Figure
4E and F) after mTHPC injection show a similar localization
pattern. At both time points, the fluorescence is preferentially seen
in the epithelia. The homogeneous fluorescence in the cytoplasm
peripheral to the dark areas, which correspond to nuclei, suggests
an intracellular localization ofthe dye. In contrast, a weak fluores-
cence is seen in the underlying lamina propria and striated muscle.
A still notable fluorescence level of the dye in the blood vessel
walls persisted up to 4 days after the injection. The highest fluo-
rescence intensity was observed at 4 days and slightly decreased
over time until 8 days.
DISCUSSION
The photodynamic efficiency and biodistribution of mTHPC were
investigated in a hamster tumour model at various times after injec-
tion in order to determine the optimal drug-light interval for PDT of
early SCC. The results of the study show that the type and severity
of tissue damage after PDT is strongly dependent on the drug-light
interval. A comparison of the structures damaged after irradiation
with the tissue localization ofthe dye, as performed here, represents
an important step in elucidating the mechanism of PDT injury at
different time points. Between 6 and 48 h after injection, mTHPC
appears to be confined essentially to the vasculature. At this time, a
massive and non-selective PDT damage is observed. Photodynamic
therapy-induced tissue damage up to 48 h after drug injection is
mainly mediated by vascular damage resulting in anoxic cell death
(Margaron et al., 1996). A more specific PDT response is seen when
treatment intervals between 4 and 8 days are used. The coagulation
necrosis observed at these longer intervals is probably due, to a large
extent, to a direct effect on the cells causing cell death accompanied
by less prominent vascular injury. This correlates with a much
higher fluorescence intensity in the epithelium compared with that
seen in the blood vessel walls. At drug-light intervals longer than 4
days after injection, mTHPC disappears almost completely from
the vasculature and consequently vascular damage progressively
decreases. The results of this study are in agreement with those
reported for other types oftumours (Ris et al., 1993a; Lofgren et al.,
1994; Peng et al., 1995).
Our previous experiments have shown the strong influence of
the applied light dose to the degree of PDT-induced damage. As
shown in Figure 5, the tissue damage increases when increasing
the applied light dose for a given light dose rate and drug-light
interval. The strong step observed in PDT damage at 24 h, with no
damage up to 2.5 J cm-2 and a transmural necrosis induced at more
than 3 J cm-2 is the result of the ischaemic vascular damage that
predominates at short drug-light intervals. However, the degree of
PDT injury observed at 4 and 8 days after the injection is a
smoother function of the light dose used. Between these time
points, the tissue damage on either mucosae decreases for the same
treatment conditions. These data further support the results ofthis
study and suggest that the time-dependent biodistribution of the
dye correlates with specific intra/extracellular sites of PDT injury
indicated by fluorescence microscopy.
It is interesting to note a slight discordance between the relative
fluorescence intensity and the degree of tissue damage on tumour
vs healthy mucosa at drug-light intervals greater than 3 days.
Photodynamic therapy performed between 3 and 8 days after
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Figure 2 Transmission photomicrographs of early SCCs and contralateral healthy mucosae after mTHPC-PDT (650 nm, 12 J cm-2, 150 mW cm-2) at different
drug-light intervals. PDT damage was assessed 96 h after light exposure. (A and B) At 12 h, a transmural necrosis is seen in both SCCs (A) and healthy
mucosa (B). Significant oedema with vascular dilatation and migration of white cells within the dilated vessels is observed as well as some areas of focal
haemorrhage (HE-stained cross-sections, 50 x, 1 cm = 200gm). (C and D) At 4 days, the SCC epithelium and underlying lamina propria are completely
destroyed by PDT, whereas the deeper muscular layers are not damaged (C). In contrast, the necrosis on the healthy mucosa is restricted to the epithelium
(D). For both irradiated mucosae, the acute inflammatory changes observed are similar, but oedema and vascular dilatation are less prominent than at 12 h
(HE-stained cross-section, 100 x, 1 cm = 100 rm). (E and F) At 8 days, the destruction of the epithelium and lamina propria are observed on early SCC only
(E). The minimal PDT injury seen on the healthy mucosae (F) is localized in the parabasal epithelial layers. A moderate inflammatory reaction, without visible
oedema and vascular dilatation, is similar for either mucosae (HE-stained cross-section, 100 x, 1 cm = 100 ,um). In order to present the whole cheek pouch wall
in A and B, because of the importance of the oedema, the magnification is reduced by half in comparison with (C-F)
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Figure 4 (A and B) Fluorescence photomicrographs and the corresponding HE staining of the hamster cheek pouch mucosa 12 h after the injection of
mTHPC. The fluorescence appears to localize mainly in the endothelial cells of the blood vessels situated in the lamina propria and in a few inflammatory cells
or macrophages surrounding the vascular bed. A weak fluorescence intensity is observed in the epithelial cells and in underlying lamina propria or striated
muscle. The fluorescence photomicrographs and corresponding HE stains recorded 4 days (C and D) and 8 days (E and F) after mTHPC injection show a
similar localization pattern. At both time points, the dye fluorescence is preferentially seen in the epithelium, and a weak fluorescence is observed in the
underlying mucosal layers (lamina propria and striated muscle). Scale bar 20 gm. E, epithelium; LP, lamina propria; SM, striated muscle; V, blood vessel
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Figure 5 PDT-induced tissue damage in early SCCs and healthy mucosae
at 650 nm 1, 4 and 8 days after the injection of 0.5 mg kg-' of mTHPC. The
fluences of 0.75 to 20J cm-2 are delivered at fluence rate of 150 mW cm-2.
Data points represent mean tissue damage, assessed 96 h after light
exposure, for three animals as determined by the rating scale described in
the text (S.D. = ±0.25). The significance of the tissue response observed
between neoplastic and healthy mucosae at various light dose and drug-light
intervals was determined using a non-parametric Mann-Whitney U-test
(a < 0.05). The S-shaped Gompertz formula curve used is described in the
Material and methods section of the text. The 'off/on' PDT effect observed at
day 1 (no damage up to 2.5 J cm-2 and a transmural necrosis induced with
3 J cm-2 and above) on early SCCs and healthy mucosa is due to the
ischaemic vascular injury that predominates at short drug-light intervals. The
degree of the PDT damage seen at 4 and 8 days is directly proportional to
the light dose used. For both drug-light intervals, the significantly higher PDT
injury is observed for early SCCs rather than for the healthy mucosa. By
prolonging the drug-light interval from 4 to 8 days, the tissue damage on
either mucosae significantly decreases for the same treatment condition
(a < 0.05). Early SCC and healthy mucosa day 1 (- -0--), early SCC
4 days ( * ), healthy mucosa 4 days ( ---O--), early SCC 8 days (*)
healthy mucosa 8 days (---F2---)
injection of mTHPC damages SCCs more than healthy mucosa
(a ' 0.05). However, the degree of damage to healthy mucosae
diminishes significantly (ax < 0.05) between these two time points.
As shown in Figures IA and B for both wavelengths applied, the
PDTdamage decreases much morerapidly for the healthy mucosa
than for the SCCs. In contrast, a weak and non-significant differ-
ence in relative fluorescence intensity is observed for early SCCs
compared with healthy mucosa. This suggests that in some cases
the fluorescence intensities may notpredict the PDT efficiency.
Our experiments also appear to indicate that PDT could be
achieved at prolonged time intervals between drug administration
and light application, that is 6 or 8 days. In this instance, the thera-
peutic ratio of mTHPC-PDT should be optimized by modulating
the light dose and iffadiance for a given drug-light interval with
minimal risks ofcomplication. Based on the information available
now, we have decided to introduce a drug-light interval of 8 days
into our clinical PDT protocols and evaluate the therapeutic
response.
In conclusion, to determnine the most favourable time for PDT of
early SCC, it is important to take into account the biodistribution
of the dye. This helps to clarify the mechanism of PDT injury at
various drug-light intervals. Apart from fluorescence microscopy,
complementary information on the pharmacokinetics and localiza-
tion patterns of the dye have been obtained already by in vivo
spectrofluorometry and chemical extraction assays. These data
will also be correlated with the PDT response described above
(Forrer et al., 1997).
The presentpreclinical evaluation, including the tissue response
at various drug-light intervals and time-dependent mTHPC
biodistribution between different mucosal layers, may help us to
optimize mTHPC use in a clinical context. The advantage of ex
vivo fluorescence microscopy compared with other methods, such
as in vivo spectrofluorometry or chemical extraction assays, lies in
the possibility ofdetermining the uptake, retention and elimination
time of the dye in separate mucosal layers such as epithelium,
lamina propria, striated muscle or blood vessels. This knowledge
allows us to evaluate the optimal time-dependent ratio of mTHPC
in different tissue compartments and hence to select the optimal
therapeutic parameters for effective PDT while minimizing the
risks ofover- or undertreatment.
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